Guard Therapeutics
- Biotech or pharma, therapeutic R&D
Guard Therapeutics is a Swedish clinical-stage biotechnology company listed on Nasdaq First North Growth Market in Stockholm. Our vision is to pioneer transformative medicines for kidney disease, eliminating the need for dialysis and kidney transplantation, by harnessing the natural properties of alpha-1-microglobulin (A1M).
Our lead candidate RMC-035, a therapeutic A1M protein, is in Phase 2b development. Results of the ongoing Phase 2b POINTER study is expected year-end 2025. RMC-035 received US FDA Fast Track Designation for kidney protection in open-heart surgery.
Our preclinical GTX platform consists of novel proprietary peptides, the next generation A1M-based drugs for the treatment of chronic kidney disease (CKD). These peptides demonstrate robust efficacy across a wide range of kidney disease models and are uniquely positioned by targeting orphan and other segments of CKD, an area of massive unmet need.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}